Protagonist Therapeutics FY 2020: net loss $66.2M; diluted EPS −$1.92
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001558370-21-002715
- Document
- 10-K
- Exhibit 4.7
- Warrants or notes
Key figures from this report
These are the numbers Protagonist Therapeutics reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$66.2MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS−$1.92No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$117.4MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$72.5MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Prestige Consumer Healthcare PBH public float $3.0B, Sep 30, 2025
- Viking Therapeutics VKTX public float $3.0B, Jun 30, 2025
- Catalyst Pharmaceuticals CPRX public float $2.5B, Jun 30, 2025
- Cytokinetics CYTK public float $2.5B, Jun 30, 2025
- TG Therapeutics TGTX public float $2.5B, Jun 30, 2025